Thymosin β4-related actin-sequestering peptide (research)
TB-500 (thymosin β4 fragment)
Actin-binding peptide domain associated with cell migration, , and repair signalling in animal models.
Primary Mechanism of Action
Clinical / Scientific
Thymosin β4 sequesters G-actin (thymosin fold), influencing cytoskeletal dynamics, cell migration, and angiogenic growth-factor expression in injury models. TB-500 is a research fragment/analogue name used in peptide markets; it is not a licensed wound-healing drug.
Pathway Targets
G-actin
Scientific explanation
Sequestration affecting cytoskeletal assembly.
Angiogenesis
Scientific explanation
Reported -related effects in models.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Receptor to physiology
Target to downstream effect: G-actin → Angiogenesis
Mechanistically Relevant Repurposed & Adjunctive Applications
Research peptide context
PreclinicalMechanistic rationale
Catalogued as a research peptide. Mechanistic statements below describe known or pathway biology and do not establish a licensed therapeutic indication.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| Actin cytoskeleton | G-actin sequestration | Migration / repair models | Preclinical |
In Plain Language
TB-500 is related to thymosin β4, a protein that holds actin (the cell’s internal scaffolding) in a ready-to-use form. Repair claims come mainly from animal and cell work.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.